Fort Sheridan Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.91M | Buy |
120,987
+3,917
| +3% | +$102K | 0.31% | 65 |
|
|
2026
Q1 | $3.29M | Sell |
117,070
-9,694
| -8% | -$258K | 0.4% | 49 |
|
|
2025
Q4 | $3.16M | Buy |
126,764
+5,526
| +5% | +$139K | 0.4% | 46 |
|
|
2025
Q3 | $3.09M | Buy |
121,238
+4,324
| +4% | +$107K | 0.4% | 45 |
|
|
2025
Q2 | $2.83M | Buy |
116,914
+25,948
| +29% | +$605K | 0.4% | 45 |
|
|
2025
Q1 | $2.31M | Buy |
90,966
+18,248
| +25% | +$478K | 0.35% | 56 |
|
|
2024
Q4 | $1.93M | Buy |
72,718
+370
| +0.5% | +$10K | 0.28% | 62 |
|
|
2024
Q3 | $2.09M | Buy |
72,348
+2,456
| +4% | +$71.6K | 0.32% | 61 |
|
|
2024
Q2 | $1.96M | Buy |
69,892
+1,427
| +2% | +$39.3K | 0.32% | 59 |
|
|
2024
Q1 | $1.9M | Sell |
68,465
-12,692
| -16% | -$352K | 0.36% | 53 |
|
|
2023
Q4 | $2.34M | Sell |
81,157
-24,432
| -23% | -$739K | 0.47% | 42 |
|
|
2023
Q3 | $3.5M | Sell |
105,589
-5,177
| -5% | -$183K | 0.79% | 25 |
|
|
2023
Q2 | $4.06M | Buy |
110,766
+6,465
| +6% | +$252K | 0.93% | 23 |
|
|
2023
Q1 | $4.26M | Buy |
104,301
+24,423
| +31% | +$1.05M | 1.08% | 19 |
|
|
2022
Q4 | $4.09M | Sell |
79,878
-2,298
| -3% | -$110K | 1.33% | 15 |
|
|
2022
Q3 | $3.6M | Buy |
82,176
+1,624
| +2% | +$78.9K | 1.21% | 15 |
|
|
2022
Q2 | $4.22M | Buy |
80,552
+538
| +0.7% | +$27.4K | 1.37% | 15 |
|
|
2022
Q1 | $4.14M | Buy |
80,014
+1,492
| +2% | +$77.4K | 1.22% | 15 |
|
|
2021
Q4 | $4.64M | Buy |
78,522
+1,730
| +2% | +$85.7K | 1.34% | 13 |
|
|
2021
Q3 | $3.3M | Buy |
76,792
+2,327
| +3% | +$103K | 1.08% | 18 |
|
|
2021
Q2 | $2.92M | Buy |
74,465
+12,885
| +21% | +$501K | 0.97% | 21 |
|
|
2021
Q1 | $2.23M | Buy |
61,580
+17,663
| +40% | +$627K | 0.89% | 23 |
|
|
2020
Q4 | $1.62M | Buy |
43,917
+1,710
| +4% | +$62.7K | 0.79% | 27 |
|
|
2020
Q3 | $1.47M | Buy |
42,207
+7,589
| +22% | +$266K | 0.87% | 23 |
|
|
2020
Q2 | $1.07M | Buy |
34,618
+6,818
| +25% | +$232K | 0.66% | 28 |
|
|
2020
Q1 | $861K | Buy |
27,800
+10,465
| +60% | +$357K | 0.63% | 29 |
|
|
2019
Q4 | $644K | Sell |
17,335
-1,688
| -9% | -$60.1K | 0.35% | 41 |
|
|
2019
Q3 | $648K | Buy |
19,023
+1,930
| +11% | +$70.2K | 0.36% | 39 |
|
|
2019
Q2 | $703K | Buy |
17,093
+1,943
| +13% | +$77.2K | 0.41% | 37 |
|
|
2019
Q1 | $610K | Hold |
15,150
| – | – | 0.4% | 36 |
|
|
2018
Q4 | $627K | Buy |
+15,150
| New | +$629K | 0.44% | 30 |
|
Other funds holding PFE
Fort Sheridan Advisors's PFE Position: Q2 2026 in Review
Fort Sheridan Advisors increased its Pfizer (PFE) stake by 3.3% in Q2 2026, buying an estimated $102K and bringing the position to 120,987 shares worth $2.91M. The position accounts for 0.31% of the portfolio, ranked #65.
Fort Sheridan Advisors first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.64M in Q4 2021. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Fort Sheridan Advisors held 120,987 shares of Pfizer worth $2.91M as of Q2 2026.
- Fort Sheridan Advisors bought 3,917 Pfizer shares in Q2 2026, an estimated $102K.
- Pfizer made up 0.31% of Fort Sheridan Advisors's portfolio in Q2 2026, its #65 holding.
- Fort Sheridan Advisors first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Fort Sheridan Advisors's Pfizer position peaked at $4.64M in Q4 2021.
- 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Fort Sheridan Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.